First Trimester Placental Growth Factor and Preterm Birth What a Prospective Cohort Study Reveals
Preterm birth often appears as a late pregnancy event, but the biology behind it may begin much earlier. One signal attracting attention is placental growth factor, or PlGF, a protein produced by the placenta that supports healthy blood vessel development. A prospective cohort study examining first-trimester PlGF suggests that low levels may help identify pregnancies at higher risk of preterm birth, especially when the pathway involves placental dysfunction.
The finding matters because preterm birth remains one of the leading causes of newborn illness and death worldwide. In India and globally, even small improvements in early risk prediction could help clinicians target closer monitoring, preventive care, and timely referral. Yet the study also carries a clear warning: PlGF is promising, but it is not ready to stand alone as a simple “preterm birth test”.
This article is for information only and should not replace clinical advice from an obstetrician or qualified healthcare professional.
Why placental growth factor matters in pregnancy
Placental growth factor is a member of the vascular endothelial growth factor family. In simple terms, it helps regulate blood vessel formation and blood flow in the placenta. During a healthy pregnancy, the placenta must build an efficient circulation system so oxygen and nutrients can move from the pregnant person to the fetus.
PlGF levels usually rise through early and mid-pregnancy. Lower-than-expected levels can reflect poor placental development, impaired blood vessel growth, or an anti-angiogenic state. These are the same biological pathways often linked with:
Preeclampsia
Fetal growth restriction
Placental insufficiency
Some forms of medically indicated preterm birth
This is why researchers are interested in the association between placental growth factor and preterm birth. If the placenta shows signs of dysfunction in the first trimester, it may provide an early warning long before symptoms appear.
PlGF is already used in some settings to support assessment of suspected preeclampsia later in pregnancy, often alongside soluble fms-like tyrosine kinase-1, known as sFlt-1. The newer question is whether PlGF measured much earlier, during the first trimester, can help predict preterm birth risk.
What the prospective cohort study examined
A prospective cohort design is well suited to this question. In this type of study, researchers enrol pregnant participants before the outcome occurs, measure the exposure of interest, then follow participants over time. That reduces recall bias and helps clarify whether the biomarker appears before the clinical outcome.
In the study discussed here, investigators measured first-trimester PlGF and then tracked pregnancy outcomes, including preterm birth. The main focus was whether lower PlGF levels in early pregnancy were associated with birth before 37 weeks.
Most studies in this field adjust PlGF values for gestational age and maternal characteristics, often reporting results as multiples of the median, or MoM. This approach helps compare results across pregnancies tested at slightly different gestational ages.
The researchers were especially interested in whether PlGF predicted all preterm births equally, or whether the signal was stronger for specific subtypes. This distinction matters because preterm birth is not one disease. It includes:
Type of preterm birth | Common pathway |
Spontaneous preterm labour | Uterine contractions begin early, often with mixed causes |
Preterm prelabour rupture of membranes | The membranes rupture before labour and before 37 weeks |
Medically indicated preterm birth | Early delivery is recommended because of maternal or fetal risk |
Placental-dysfunction-related preterm birth | Preeclampsia, fetal growth restriction, or abnormal placental function often play a role |
The key biological argument is that first-trimester PlGF should be most closely linked with placental-dysfunction-related preterm birth, rather than every preterm birth subtype.
Key findings from the study
The study found that lower first-trimester PlGF was associated with a higher risk of preterm birth. The association was more apparent when researchers looked at earlier preterm birth and cases likely connected to placental dysfunction.
That pattern fits the biology. A low PlGF result early in pregnancy may reflect a placenta that has not developed its blood supply as effectively as expected. Later, that same impaired placental function may contribute to preeclampsia, poor fetal growth, or a need for earlier delivery.
The study’s statistical message can be summarised in three main points.
Low PlGF marked a higher-risk group
Participants with lower PlGF levels had a higher rate of preterm birth than those with PlGF values in the expected range. Depending on the cut-off used, such as the lowest fifth or tenth percentile, the low-PlGF group showed increased risk.
This does not mean most people with low PlGF delivered preterm. It means the probability was higher compared with the reference group. That distinction is central to interpreting biomarker studies.
A useful way to frame the finding is this: low PlGF improved risk stratification, but it did not make preterm birth predictable with certainty.
The association was stronger for early and indicated preterm birth
The signal was not uniform across all preterm births. The study suggested a stronger relationship between low PlGF and preterm births linked to placental disease, such as those associated with preeclampsia or fetal growth restriction.
This matters clinically. Spontaneous preterm birth may arise from infection, cervical shortening, uterine overdistension, inflammation, or other pathways. A placental angiogenic marker may not capture all those risks.
By contrast, medically indicated early delivery due to preeclampsia or fetal compromise is more directly connected to placental biology. PlGF is therefore more plausible as a marker for that pathway.
PlGF alone had limited screening performance
The study did not support using PlGF as a stand-alone screening tool for preterm birth. Even when an association is statistically significant, a biomarker may still have limited sensitivity, specificity, or positive predictive value.
This is a common issue in obstetric screening. Preterm birth is multifactorial, and one marker rarely captures enough of the risk. The more practical role for PlGF may be as part of a broader model that includes:
Maternal history
Prior preterm birth
Blood pressure
Body mass index
Smoking or tobacco exposure
Uterine artery Doppler findings
Cervical length
Other biochemical markers
Socio-environmental and infection-related risk factors
The investigators’ interpretation was cautious: first-trimester PlGF appears to reflect early placental health, but its value is likely greatest when combined with clinical and ultrasound-based risk factors.
That is a measured conclusion, and it is the right one. A useful biomarker does not need to be perfect. It needs to improve decision-making when added to existing care.
How to interpret the statistics
Biomarker studies often report several kinds of statistics. Each answers a different question. Understanding them helps prevent overreading the results.
Statistic | What it tells us | Why it matters |
Relative risk or odds ratio | How much higher the risk is in the low-PlGF group | Shows strength of association |
Confidence interval | The range of values compatible with the data | Shows precision of the estimate |
Sensitivity | How many future preterm births were detected by the marker | Affects usefulness for screening |
Specificity | How many non-preterm births were correctly classified as lower risk | Affects false-positive rates |
Area under the curve | Overall discrimination between higher and lower risk | Shows predictive performance |
Positive predictive value | How many positive screens truly had the outcome | Depends heavily on how common the outcome is |
A statistically significant association does not automatically equal a clinically useful test. For example, if a low PlGF cut-off identifies a higher-risk group but misses many future preterm births, it may not be suitable as a universal screen. If it produces too many false positives, it may increase anxiety and unnecessary follow-up.
The most useful result would be a model that combines PlGF with other predictors and meaningfully improves calibration and discrimination. In practice, that means the model should identify more high-risk pregnancies without labelling too many low-risk pregnancies as high risk.
Why first-trimester prediction is appealing
The first trimester is a valuable window for prevention. Many routine assessments already happen during this period, including dating scans, aneuploidy screening, and baseline risk review.
If PlGF testing can be integrated into early pregnancy care, it may allow clinicians to:
Identify pregnancies needing closer blood pressure monitoring
Watch more carefully for fetal growth restriction
Plan additional ultrasound surveillance
Consider aspirin prophylaxis where clinically appropriate and guideline-supported
Refer high-risk pregnancies earlier to specialist obstetric care
This is especially relevant in settings where delayed recognition of preeclampsia or fetal growth restriction can lead to emergency care. Early risk information could support planned monitoring rather than reactive intervention.
At the same time, the ethical side matters. Any screening test used in early pregnancy must be accurate enough to justify the anxiety, cost, and follow-up it creates. False reassurance is also a concern. A normal PlGF result should not lead clinicians to ignore symptoms or other risk factors.
What the study adds to the evidence
The study adds to a growing body of evidence that preterm birth risk begins to separate early in pregnancy for some patients. It supports the view that placental dysfunction can be detectable before overt clinical disease appears.
Its strengths include the prospective design, early biomarker measurement, and follow-up to pregnancy outcomes. These features make the findings more informative than studies that measure biomarkers only after symptoms begin.
The study also helps refine the question. Rather than asking, “Can PlGF predict preterm birth?” the better question is:
Which kinds of preterm birth does PlGF help predict, in which populations, and when added to which other risk factors?
That shift is important. Preterm birth has many causes. A single biological marker should not be expected to predict infection-related, cervical, inflammatory, and placental pathways equally well.
Clinical implications should remain cautious
The findings are promising, but they should not be translated into routine stand-alone testing without further validation.
For clinicians, low first-trimester PlGF may be best viewed as a risk signal. It can prompt closer attention to placental-disease pathways, especially when other risk factors are present. It should not be used in isolation to make major care decisions.
For patients, a low PlGF result would not mean preterm birth is inevitable. Many pregnancies with low biomarker levels continue to term. Similarly, a normal PlGF result does not remove all risk.
For health systems, the main question is whether adding PlGF to early pregnancy screening improves outcomes enough to justify cost and implementation. This is especially important in India, where access to advanced biomarker testing varies widely between urban tertiary centres and smaller facilities.
What future research should focus on
The next phase of research should move from association to clinical usefulness. Several areas need attention.
Larger and more diverse cohorts
Studies should include participants from varied ethnic, geographic, nutritional, and socioeconomic backgrounds. A model built in one population may not perform the same way in another. This is especially relevant for South Asian populations, where baseline risks and healthcare access patterns may differ from Western cohorts.
Clear separation of preterm birth subtypes
Future studies should report spontaneous, medically indicated, early, late, and placental-dysfunction-related preterm birth separately. Combining them into one outcome can dilute meaningful associations.
Combined prediction models
PlGF should be tested alongside uterine artery Doppler, maternal history, blood pressure, cervical length, and other biomarkers. The key question is whether it improves prediction beyond tools already available.
Intervention trials
Prediction only matters if it leads to better care. Future trials should test whether PlGF-guided monitoring or prevention reduces preterm birth, severe preeclampsia, fetal growth restriction, neonatal intensive care admission, or perinatal mortality.
Cost-effectiveness in real-world care
Even a useful biomarker must be affordable and practical. Research should assess whether testing can be implemented in public and private antenatal care settings, including lower-resource areas.
The takeaway
The prospective cohort study strengthens the case that first-trimester PlGF is linked with later preterm birth risk, particularly when placental dysfunction is part of the pathway. The result is biologically plausible, clinically interesting, and worth further study.
The most balanced interpretation is this: PlGF is not a stand-alone answer to preterm birth prediction. It is an early placental signal that may become useful when combined with maternal history, ultrasound findings, and other clinical markers.
For now, the finding should encourage better research, not premature overuse. The future of preterm birth prediction will likely depend on integrated models that recognise the many different routes to early delivery, while giving clinicians enough time to act before complications become urgent.
Comments